Full Press Release Details
PAIN THERAPEUTICS ANNOUNCES FOURTH QUARTER AND YEAR-END 2006 FINANCIAL RESULTS
SOUTH SAN FRANCISCO, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Pain
Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today reported
financial results for the year and fourth quarter ended December 31, 2006.
The net income for the year ended December 31, 2006 was $6.2 million, or
$0.14 per share, compared to a net loss of $30.7 million, or $0.70 per share,
for the same period of 2005. The net loss for the quarter ended December 31,
2006 was $5.7 million, or $0.13 per share, compared to a net loss of $3.1
million, or $0.07 per share for the fourth quarter of 2005.
"2006 was a year marked by meaningful progress," said Remi Barbier, Pain
Therapeutics' president and chief executive officer. "We achieved several key
drug development goals, advanced a new drug candidate into clinical development
and in-licensed a new initiative in oncology. On the corporate side, we made
important hires that added new technical talent to the team, and we continued to
build on our financial strength, ending the year with over $204 million in
At December 31, 2006 Pain Therapeutics' cash, cash equivalents and
marketable securities were $204.4 million. The Company expects its net cash
requirements for 2007 to be approximately $10 million.
"In 2007, our strategy is to enhance our leadership position in drug
development," added Remi Barbier. "We are positioned to make progress on
multiple fronts in the coming year, most visibly in the clinic. We anticipate
completing a pivotal Phase III study with Remoxy(TM), which we believe may be
the first abuse-resistant opioid painkiller to eventually reach the marketplace.
We also anticipate the continued clinical development of Oxytrex(TM), which is
in a Phase III study in patients who are dependent on extremely high doses of
oxycodone. In the first half of 2007, we also expect to begin a first-in-man
Phase I study with an important new drug candidate for metastatic melanoma. As
we advance our clinical pipeline during the year, we also expect to build our
early-stage pipeline through a combination of in- house research efforts or
in-licensing opportunities that fit our business model. Collectively, we believe
these efforts in 2007 harness the skills and creativity of our dedicated team."
Financial Highlights
* We have a collaboration with King Pharmaceuticals, Inc. ("King") to
develop abuse-resistant opioid painkillers. King gave us an upfront
payment of $150 million in December 2005.
* For accounting purposes, we plan to recognize a portion of the upfront
payment as program fee revenue each quarter through mid- 2011. Program
fee revenue for the year ended December 31, 2006 was $26.2 million,
compared to $3.7 million for the same period of 2005.
* On January 1, 2006 we adopted Statement No. 123( R ), Share-Based
Payment, or FAS 123R. In adopting FAS 123R, we began to recognize
employee non-cash stock-based compensation related expenses in our
financial statements.
* Collaboration revenue for the year ended December 31, 2006 was $22.7
million, compared to $1.4 million for the same period of 2005.
Collaboration revenue for the fourth quarter of 2006 decreased to a
negative amount of $214,000 because certain expenses we incurred in
the third and fourth quarter of 2006 continue to be subject to
completion of review by King.
* Research and development expenses for the fourth quarter ended
December 31, 2006 increased to $13.3 million from $7.2 million for the
same period of 2005. Research and development expenses for the year
ended December 31, 2006 increased to $46.8 million from $32.9 million
for the same period of 2005. These increases were primarily due to the
Phase III programs for Remoxy and Oxytrex, the Phase I clinical
program for PTI-202, increases in development activities relating to
our new program in metastatic melanoma and increases in non-cash
stock-related compensation costs associated with the adoption of FAS
* General and administrative expenses increased to $2.0 million from
$1.6 million in the three months ended December 31, 2006 and 2005,
respectively, and to $7.7 million from $4.9 million in the twelve
months ended December 31, 2006 and 2005, respectively. The increases
were primarily due to increases in non-cash stock-related compensation
costs associated with the adoption of FAS 123R.
* We have a provision for income taxes of $2.9 million for the year
ended December 31, 2006. We lowered our estimate of income taxes
stemming from alternative minimum taxes by $0.7 million during the
quarter ended December 31, 2006.
About Pain Therapeutics, Inc.
Pain Therapeutics is a biopharmaceutical company that develops novel drugs
for pain management and oncology. We have three investigational drug candidates
in clinical programs. Remoxy and PTI-202 are proprietary, abuse- resistant forms
of opioid drugs. Oxytrex is a novel, next-generation painkiller that potentially
offers less physical dependence than currently marketed opioid painkillers. We
are also developing a novel radio-labeled monoclonal antibody to treat
metastatic melanoma, a rare but deadly form of skin cancer. The FDA has not yet
evaluated the merits, safety or efficacy of our drug candidates. For more
information, please consult our website: www.paintrials.com.
Note Regarding Forward-Looking Statements: This press release contains
forward-looking statements for purposes of the Private Securities Litigation
Reform Act of 1995 (the "Act"). PTI disclaims any intent or obligation to update
these forward-looking statements, and claims the protection of the Safe Harbor
for forward-looking statements contained in the Act. Examples of such statements
include, but are not limited to, any statements relating to the timing, scope or
expected outcome of the Company's clinical development of its drug candidates,
its plans for advancing its early-stage pipeline, the Company's expected net
cash requirements in 2007, and the potential benefits of the Company's drug
candidates. Such statements are based on management's current expectations, but
actual results may differ materially due to various factors. Such statements
involve risks and uncertainties, including, but not limited to, those risks and
uncertainties relating to difficulties or delays in development, testing,
regulatory approval, production and marketing of the Company's drug candidates,
unexpected adverse side effects or inadequate therapeutic efficacy of the
Company's drug candidates that could slow or prevent product approval or market
acceptance (including the risk that current and past results of clinical trials
are not necessarily indicative of future results of clinical trials), the
uncertainty of patent protection for the Company's intellectual property or
trade secrets, the Company's ability to obtain additional financing if necessary
and unanticipated research and development and other costs. For further
information regarding these and other risks related to the Company's business,